An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast

Current Medical Research and Opinion

Volumn 24, Issue 5, 2008, Pages 1529-1538

  Gottlieb, Alice B ^a,e   Strober, B ^b   Krueger, J G ^c   Rohane, P ^d   Zeldis, J B ^d   Hu, C C ^d   Kipnis, C ^d  

^a TUFTS UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d CELGENE CORPORATION   (United States)

^e TUFTS MEDICAL CENTER   (United States)

Author keywords

Apremilast; Epidermal thickness; Phosphodiesterase 4 inhibitor; Psoriasis; Psoriasis area and severity index (PASI); Static physician's global assessment (sPGA)

Indexed keywords

ANTIINFLAMMATORY AGENT; APREMILAST; GLYCOPROTEIN P 15095; LIPOPOLYSACCHARIDE; MARKER; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BIOLOGICAL ACTIVITY; BODY SURFACE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; DERMIS; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG INHIBITION; EPIDERMIS; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; IN VITRO STUDY; LABORATORY TEST; MALE; MONITORING; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PATHOGENESIS; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PSORIASIS VULGARIS; RATING SCALE; SKIN BIOPSY; T LYMPHOCYTE;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS; BIOPSY, NEEDLE; CONFIDENCE INTERVALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIDERMIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PILOT PROJECTS; PSORIASIS; SEVERITY OF ILLNESS INDEX; THALIDOMIDE; TREATMENT OUTCOME;

EID: 44349161096     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X301866     Document Type: Article

References (13)

1. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-20
2. Anti-inflammatory activities of the novel PDE4 inhibitor CC-10004 against human leukocytes in vitro; Celgene Report Number 5042-107; July 1, 2004
3. Evaluation of anti-arthritic activity in the mAB/LPS-induced experimental murine arthritogenic model; Celgene Report Number CLG/002/EM; April 20, 2004
4. Gottlieb AB, Masud S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003;48:68-75
5. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002;46:886-91
6. Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138:591-600
7. Oestreicher JL, Walters IB, Kikuchi T, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 2001;1:272-87
8. Frederiksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978;157:238-44
9. Kruger J, Gottlieb A, Lebwohl M, et al. Safety, pharmacokinetics and histopathological effects of an oral P38 MAP kinase inhibitor (BIRB 796 BS), administered twice daily for 28 days in plaque-type psoriasis. The 9th International Psoriasis Symposium, New York, NY, June 17-22, 2003
10. Timmer W, Leclerc V, Birraux G, et al. The new phosphodiseterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-α ex vivo. J Clin Pharmacol 2002;42:297-303
11. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7
12. Gottlieb AB. Tumor necrosis factor blockade: mechanism of action. J Investig Dermatol Symp Proc 2007;12:1-4
13. Numerof RP, Asadullah K. Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. BioDrugs 2006;20;93-103